New York, Sept. 12 – Citigroup Global Markets Holdings Inc. priced $10 million of contingent income autocallable securities due Sept. 12, 2024 linked to the SPDR S&P Biotech ETF, according to a 424B2 filing with the Securities and Exchange Commission.
Investors will receive a coupon of 15.1%, paid quarterly, if the underlying fund closes at or above its 87% downside threshold on the related quarterly observation date.
The securities will be called automatically starting Dec. 6 at par if the price of the underlying stock is greater than or equal to its initial price on any quarterly review date.
At maturity the payout will be par unless the ETF declines by more than its 13% buffer in which case investors will lose 114.943% of the decline beyond the buffer.
The notes are guaranteed by Citigroup Inc.
Citigroup Global Markets Inc. is the agent.
| Issuer: | Citigroup Global Markets Holdings Inc.
|
| Guarantor: | Citigroup Inc.
|
| Issue: | Contingent income autocallable securities
|
| Underlying ETF: | SPDR S&P Biotech ETF
|
| Amount: | $10 million
|
| Maturity: | Sept. 12, 2024
|
| Coupon: | 15.1%, paid quarterly, if the underlying fund closes at or above its 87% downside threshold on the related quarterly observation date
|
| Price: | Par
|
| Payout at maturity: | Par unless the ETF declines by more than its buffer in which case investors will lose 114.943% of the decline beyond the buffer
|
| Call: | Automatically starting Dec. 6 at par if the price of the underlying stock is greater than or equal to its initial price on any quarterly review date
|
| Initial level: | $79.65
|
| Buffer: | 13%
|
| Downside leverage: | 114.943%
|
| Pricing date: | Sept. 6
|
| Settlement date: | Sept. 11
|
| Agent: | Citigroup Global Markets Inc.
|
| Fees: | 0.1% including a structuring fee of 0.05%
|
| Cusip: | 17291QCV4
|
|
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
